Truist Securiti Analysts Reduce Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) – Equities researchers at Truist Securiti reduced their Q4 2021 earnings per share estimates for shares of Merck & Co., Inc. in a note issued to investors on Tuesday, November 23rd. Truist Securiti analyst R. Karnauskas now anticipates that the company will earn $1.22 per share for the quarter, down from their prior forecast of $1.42. Truist Securiti also issued estimates for Merck & Co., Inc.’s FY2023 earnings at $6.35 EPS.

Several other equities analysts have also commented on MRK. Truist raised their price objective on Merck & Co., Inc. from $92.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Securities lifted their price target on Merck & Co., Inc. from $92.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. Argus raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a research report on Monday, November 1st. Berenberg Bank reaffirmed a “hold” rating and issued a $92.00 price target (up previously from $86.00) on shares of Merck & Co., Inc. in a research report on Sunday, October 10th. Finally, Barclays lifted their price target on Merck & Co., Inc. from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Monday, November 1st. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $95.73.

Shares of Merck & Co., Inc. stock opened at $82.28 on Thursday. The company has a current ratio of 1.31, a quick ratio of 1.07 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $207.83 billion, a P/E ratio of 29.07, a P/E/G ratio of 2.11 and a beta of 0.46. The business has a fifty day simple moving average of $80.68 and a two-hundred day simple moving average of $78.07. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $91.40.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Wednesday, October 27th. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.55 by $0.20. The business had revenue of $13.15 billion during the quarter, compared to analyst estimates of $12.32 billion. Merck & Co., Inc. had a return on equity of 48.21% and a net margin of 14.64%. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.74 earnings per share.

A number of hedge funds and other institutional investors have recently bought and sold shares of MRK. OLD Mission Capital LLC purchased a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $247,000. Voloridge Investment Management LLC raised its holdings in shares of Merck & Co., Inc. by 170.1% during the 1st quarter. Voloridge Investment Management LLC now owns 47,988 shares of the company’s stock worth $3,699,000 after acquiring an additional 30,223 shares in the last quarter. Axiom Investment Management LLC raised its holdings in shares of Merck & Co., Inc. by 274.3% during the 1st quarter. Axiom Investment Management LLC now owns 4,604 shares of the company’s stock worth $355,000 after acquiring an additional 3,374 shares in the last quarter. Optiver Holding B.V. purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $1,196,000. Finally, Sargent Bickham Lagudis LLC raised its holdings in shares of Merck & Co., Inc. by 7.3% during the 1st quarter. Sargent Bickham Lagudis LLC now owns 25,183 shares of the company’s stock worth $1,941,000 after acquiring an additional 1,724 shares in the last quarter. 71.79% of the stock is currently owned by institutional investors.

In related news, insider Sanat Chattopadhyay sold 24,619 shares of the business’s stock in a transaction that occurred on Friday, October 29th. The stock was sold at an average price of $87.32, for a total transaction of $2,149,731.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kenneth C. Frazier sold 663,881 shares of the business’s stock in a transaction that occurred on Tuesday, November 9th. The shares were sold at an average price of $82.26, for a total value of $54,610,851.06. The disclosure for this sale can be found here. Insiders sold a total of 936,784 shares of company stock valued at $78,682,559 over the last quarter. 0.32% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Further Reading: What is insider trading?

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.